Off-label uses of olanzapine Review article
Article Sidebar
Published:
Jun 30, 2013
Keywords:
olanzapine, off-label indications
Main Article Content
Abstract
Olanzapine is an atypical antipsychotic, registered in schizophrenia treatment and bipolar treatment. Its multiple receptor mechanisms of action and multiple forms of administration enable the effective pharmacotherapy of many symptoms, syndromes, and diseases, beyond the list of official registrations. In this article off-label olanzapine indications were reviewed.
Article Details
Issue
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Leslie DL, Rosenheck R. Off-label use of antipsychotic medications in medicaid. Am J Manag Care 2012; 18: 109-117.
2. Rosenheck R, Leslie D, Sernyak M. From clinical trials to realworld practice: use of atypical antipsychotic medication nationally in the Department of Veterans Affairs. Med Care 2001; 39: 302-308.
3. Łoza B. Pozarejestracyjne zastosowanie leków psychotropowych. Neuropsychiatria 2012; 4 (1): 5-10.
4. www.bazalekow.mp.pl
5. Łoza B. Leki w postaci tabletek rozpuszczających się w ustach. Neuropsychiatria 2012; 2: 17-23.
6. Taylor D, Paton C, Kervin R. Przewodnik psychofarmakoterapii. Via Medica, Gdańsk 2008: 389-391.
7. Fontaine CS, Hynan LS, Koch K, Martin-Cook K, Svetlik D, Weiner MF. A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. J Clin Psychiatry 2003; 64 (6): 726-730.
8. Reeves RR, Torres RA. Orally disintegrating olanzapine for the treatment of psychotic and behavioral disturbances associated with dementia. South Med J 2003; 96 (7): 699-701.
9. Kranzler HR, Edenberg HJ. Pharmacogenetics of alcohol and alcohol dependence treatment. Curr Pharm Des 2010; 16 (19): 2141-2148.
10. Hutchison KE, Swift R, Rohsenow DJ, Monti PM, Davidson D, Almeida A. Olanzapine reduces urge to drink after drinking cues and a priming dose of alcohol. Psychopharmacology (Berl) 2001;155(1):27-34.
11. Taylor D, Paton C., Kervin R. Przewodnik psychofarmakoterapii. Via Medica; Gdańsk 2008; 328.
12. Schoemaker J, Naber D, Vrijland P, Panagides J, Emsley R. Long-term assessment of Asenapine vs. Olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry 2010; 43 (4): 138-146.
13. Schoemaker J, Stet L, Vrijland P, Naber D, Panagides J, Emsley R. Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study. Pharmacopsychiatry 2012; 45 (5): 196-203.
14. Rybakowski J. Depresja lekooporna: rozpoznawanie i postępowanie. Przewodnik Lekarza 2012; 15 (1).
15. Duvvuri V, Cromley T, Klabunde M, Boutelle K, Kaye WH. Differential weight restoration on olanzapine versus fluoxetine in identical twins with anorexia nervosa. Int J Eat Disord 2012; 45 (2): 294-297.
16. Gunderson JG. Borderline Personality Disorder. N Engl J Med 2011; 364: 2037-2042.
17. Zanarini MC, Schulz SC, Detke HC, Tanaka Y, Zhao F, Lin D, Deberdt W, Kryzhanovskaya L, Corya S. A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2011; 72 (10): 1353-1362.
18. McCracken JT, Suddath R, Chang S, Thaku S, Piacentini J. Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome. J Child Adolesc Psychopharmacol 2008; 18 (5): 501-508.
19. Olanzapine in Tourette’s syndrome: a report of three cases. Actas Esp Psiquiatr 2002; 30 (2): 129-132.
20. van den Eynde F, Naudts KH, De Saedeleer S, van Heeringen C, Audenaert K. Olanzapine in Gilles de la Tourette syndrome: beyond tics. Acta Neurol Belg 2005; 105 (4): 206-211.
21. Stamenkovic M, Schindler SD, Aschauer HN, De Zwaan M, Willinger U, Resinger E, Kasper S. Effective open-label treatment of Tourette’s disorder with olanzapine. Int Clin Psychopharmacol 2000; 15 (1): 23-28.
22. Hwang WJ. Olanzapine treatment for tics in an adult woman with severe Tourette syndrome. Acta Neurol Taiwan 2012; 21(4): 165-168.
23. Kozian R, Friederich M. Gilles-de-la-Tourette Syndrome as a Tardive Dyskinesia Psychiatr Prax 2007; 34 (5): 253-254.
24. Paleacu D, Anca M, Giladi N. Olanzapine in Huntington’s disease. Acta Neurol Scand 2002; 105 (6): 441-444.
25. Bonelli RM; Mahnert FA; Niederwieser G. Olanzapine for Huntington’s disease: an open label study. Clin Neuropharmacol 2002; 25 (5): 263-265.
26. Laks J, Rocha M, Capitäo C, Domingues RC, Ladeia G, Lima M, Engelhardt E. Functional and motor response to low dose olanzapine in Huntington’s disease: case report. Arq Neuropsiquiatr 2004; 62 (4): 1092-1094.
27. Czekalla J, Wagner T, Schacht A, Kluge M, Kinon B. Effectiveness and medication acceptance of olanzapine disintegrating tablets compared to standard olanzapine tablets in acutely treated psychiatric patients. Patient Prefer Adherence 2007; 1: 19-27.
2. Rosenheck R, Leslie D, Sernyak M. From clinical trials to realworld practice: use of atypical antipsychotic medication nationally in the Department of Veterans Affairs. Med Care 2001; 39: 302-308.
3. Łoza B. Pozarejestracyjne zastosowanie leków psychotropowych. Neuropsychiatria 2012; 4 (1): 5-10.
4. www.bazalekow.mp.pl
5. Łoza B. Leki w postaci tabletek rozpuszczających się w ustach. Neuropsychiatria 2012; 2: 17-23.
6. Taylor D, Paton C, Kervin R. Przewodnik psychofarmakoterapii. Via Medica, Gdańsk 2008: 389-391.
7. Fontaine CS, Hynan LS, Koch K, Martin-Cook K, Svetlik D, Weiner MF. A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. J Clin Psychiatry 2003; 64 (6): 726-730.
8. Reeves RR, Torres RA. Orally disintegrating olanzapine for the treatment of psychotic and behavioral disturbances associated with dementia. South Med J 2003; 96 (7): 699-701.
9. Kranzler HR, Edenberg HJ. Pharmacogenetics of alcohol and alcohol dependence treatment. Curr Pharm Des 2010; 16 (19): 2141-2148.
10. Hutchison KE, Swift R, Rohsenow DJ, Monti PM, Davidson D, Almeida A. Olanzapine reduces urge to drink after drinking cues and a priming dose of alcohol. Psychopharmacology (Berl) 2001;155(1):27-34.
11. Taylor D, Paton C., Kervin R. Przewodnik psychofarmakoterapii. Via Medica; Gdańsk 2008; 328.
12. Schoemaker J, Naber D, Vrijland P, Panagides J, Emsley R. Long-term assessment of Asenapine vs. Olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry 2010; 43 (4): 138-146.
13. Schoemaker J, Stet L, Vrijland P, Naber D, Panagides J, Emsley R. Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study. Pharmacopsychiatry 2012; 45 (5): 196-203.
14. Rybakowski J. Depresja lekooporna: rozpoznawanie i postępowanie. Przewodnik Lekarza 2012; 15 (1).
15. Duvvuri V, Cromley T, Klabunde M, Boutelle K, Kaye WH. Differential weight restoration on olanzapine versus fluoxetine in identical twins with anorexia nervosa. Int J Eat Disord 2012; 45 (2): 294-297.
16. Gunderson JG. Borderline Personality Disorder. N Engl J Med 2011; 364: 2037-2042.
17. Zanarini MC, Schulz SC, Detke HC, Tanaka Y, Zhao F, Lin D, Deberdt W, Kryzhanovskaya L, Corya S. A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2011; 72 (10): 1353-1362.
18. McCracken JT, Suddath R, Chang S, Thaku S, Piacentini J. Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome. J Child Adolesc Psychopharmacol 2008; 18 (5): 501-508.
19. Olanzapine in Tourette’s syndrome: a report of three cases. Actas Esp Psiquiatr 2002; 30 (2): 129-132.
20. van den Eynde F, Naudts KH, De Saedeleer S, van Heeringen C, Audenaert K. Olanzapine in Gilles de la Tourette syndrome: beyond tics. Acta Neurol Belg 2005; 105 (4): 206-211.
21. Stamenkovic M, Schindler SD, Aschauer HN, De Zwaan M, Willinger U, Resinger E, Kasper S. Effective open-label treatment of Tourette’s disorder with olanzapine. Int Clin Psychopharmacol 2000; 15 (1): 23-28.
22. Hwang WJ. Olanzapine treatment for tics in an adult woman with severe Tourette syndrome. Acta Neurol Taiwan 2012; 21(4): 165-168.
23. Kozian R, Friederich M. Gilles-de-la-Tourette Syndrome as a Tardive Dyskinesia Psychiatr Prax 2007; 34 (5): 253-254.
24. Paleacu D, Anca M, Giladi N. Olanzapine in Huntington’s disease. Acta Neurol Scand 2002; 105 (6): 441-444.
25. Bonelli RM; Mahnert FA; Niederwieser G. Olanzapine for Huntington’s disease: an open label study. Clin Neuropharmacol 2002; 25 (5): 263-265.
26. Laks J, Rocha M, Capitäo C, Domingues RC, Ladeia G, Lima M, Engelhardt E. Functional and motor response to low dose olanzapine in Huntington’s disease: case report. Arq Neuropsiquiatr 2004; 62 (4): 1092-1094.
27. Czekalla J, Wagner T, Schacht A, Kluge M, Kinon B. Effectiveness and medication acceptance of olanzapine disintegrating tablets compared to standard olanzapine tablets in acutely treated psychiatric patients. Patient Prefer Adherence 2007; 1: 19-27.